- Conditions
- Seizures
- Interventions
- Midazolam, Diazepam
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 1 Week to 17 Years
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Epilepsy
- Interventions
- Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category
- Drug
- Lead sponsor
- Aquestive Therapeutics
- Industry
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 6
- States / cities
- Honolulu, Hawaii • Boise, Idaho • Voorhees Township, New Jersey + 3 more
- Conditions
- Epilepsy, Focal Cortical Dysplasia, Tuberous Sclerosis, Hemimegalencephaly, Polymicrogyria, Rasmussen Encephalitis, Sturge-Weber Syndrome, Gliosis, Stroke, Tumor, Brain
- Interventions
- Intra-operative brain tonometry
- Device
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Partial Onset Seizures
- Interventions
- Pregabalin Dose Level 1, Pregabalin Dose Level 2, Placebo
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 1 Month to 3 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 5
- States / cities
- Orlando, Florida • Tampa, Florida • Houston, Texas + 1 more
- Conditions
- GNAO1
- Interventions
- Not listed
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Epileptic Encephalopathy, SCN2A Encephalopathy
- Interventions
- 1mg elsunersen, 0.5mg elsunersen
- Drug
- Lead sponsor
- Praxis Precision Medicines
- Industry
- Eligibility
- 1 Day to 18 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- San Diego, California • Aurora, Colorado • Chicago, Illinois + 3 more
- Conditions
- Epilepsy, Partial, Epilepsy, Localization Related
- Interventions
- Oxcarbazepine, Levetiracetam, Lamotrigine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 5 Years to 16 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • San Diego, California • Aurora, Colorado + 11 more
- Conditions
- Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epileptic Syndromes
- Interventions
- XEN496, Placebo
- Drug
- Lead sponsor
- Xenon Pharmaceuticals Inc.
- Industry
- Eligibility
- 1 Month to 6 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 11
- States / cities
- Orange, California • San Francisco, California • Aurora, Colorado + 8 more
- Conditions
- Childhood Absence Epilepsy
- Interventions
- Cannabidiol Oral Solution
- Drug
- Lead sponsor
- Radius Pharmaceuticals, Inc.
- Industry
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 11
- States / cities
- Miami, Florida • Tampa, Florida • Atlanta, Georgia + 8 more
- Conditions
- Epilepsy
- Interventions
- Not listed
- Lead sponsor
- Sarah Katie Ihnen
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Epilepsies, Partial
- Interventions
- SPN-804O
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Loxahatchee Groves, Florida • Tampa, Florida + 5 more
- Conditions
- Lennox Gastaut Syndrome
- Interventions
- Carisbamate
- Drug
- Lead sponsor
- SK Life Science, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Lebanon, New Hampshire • Portland, Oregon + 2 more
- Conditions
- Infantile Spasms
- Interventions
- Ganaxolone, Placebo
- Drug · Other
- Lead sponsor
- Marinus Pharmaceuticals
- Industry
- Eligibility
- 4 Months to 24 Months
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 10 more
- Conditions
- Epilepsy
- Interventions
- Diazepam Buccal Film
- Drug
- Lead sponsor
- Aquestive Therapeutics
- Industry
- Eligibility
- 2 Years to 16 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Gulf Breeze, Florida • New Brunswick, New Jersey + 6 more
- Conditions
- Epilepsy
- Interventions
- lamotrigine
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 1 Month to 24 Months
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 41
- States / cities
- Mobile, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 36 more
- Conditions
- Epilepsy
- Interventions
- Music Therapy
- Behavioral
- Lead sponsor
- Seton Healthcare Family
- Other
- Eligibility
- 6 Years to 16 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Intractable Epilepsy, Convulsive Seizures
- Interventions
- methylprednisolone sodium succinate, Placebo
- Drug · Other
- Lead sponsor
- Louisiana State University Health Sciences Center in New Orleans
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Infantile Spasms
- Interventions
- Ganaxolone
- Drug
- Lead sponsor
- Marinus Pharmaceuticals
- Industry
- Eligibility
- 4 Months to 24 Months
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 10 more
- Conditions
- Developmental and Epileptic Encephalopathy
- Interventions
- gene therapy
- Drug
- Lead sponsor
- Capsida Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Months to 7 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • New York, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- Epilepsy, Epilepsies, Partial
- Interventions
- oxcarbazepine
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 1 Month to 3 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 21 more
- Conditions
- Neonatal Epilepsy, Infantile Epilepsy
- Interventions
- Genomic Sequencing
- Genetic
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- SCN2A-DEE, Epilepsy
- Interventions
- PRAX-222 - Initial Dose, PRAX-222 - Initial Ascending Doses, PRAX-222 - Optional Ascending Doses, PRAX-222 - Fixed Doses, Placebo
- Drug · Procedure
- Lead sponsor
- Praxis Precision Medicines
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Partial Epilepsy
- Interventions
- Xcopri
- Drug
- Lead sponsor
- SK Life Science, Inc.
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Palo Alto, California • Sacramento, California + 21 more
- Conditions
- Epilepsy
- Interventions
- Lacosamide
- Drug
- Lead sponsor
- Le Bonheur Children's Hospital
- Other
- Eligibility
- 4 Years to 35 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee